Abstract
The mammalian target of rapamycin (mTOR) is the catalytic subunit of two multiprotein complexes, mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2). Clinically used rapamycin and rapalogs are FKBP12-dependent allosteric inhibitors of mTORC1. The recently discovered WYE-125132 and related drugs represent a new generation of ATP competitive and highly specific inhibitors targeting mTOR globally. As mTORC1 and mTORC2 mediate diverse sets of both redundant and distinctive cellular pathways of growth, nutrient and energy homeostasis, rapamycin and WYE-125132 elicit both overlapping and distinctive pharmacological properties with important implications in treating cancer, metabolic, and age-related degenerative diseases. Detailed methods are described for the determination of mTOR inhibition by rapamycin and WYE-125132 in assays of recombinant mTOR enzyme, immunprecipitated native mTOR complexes, growth factor- and amino acid-induced cellular phosphorylation cascades as well as the PI3K/AKT/mTOR hyperactive breast tumor model in vitro and in vivo. The methods have been particularly useful in discovery and biochemical characterization of mTOR inhibitors, cellular and in vivo mTOR substrate phosphorylation analysis, and in deciphering novel biomarkers of mTORC1 and mTORC2 signaling pathways.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298, 1912–34
Abraham RT (2004) PI 3-kinase related kinases: ‘big’ players in stress-induced signaling pathways. DNA Repair (Amst) 3, 883–7
Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124, 471–84
Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12, 9–22
Yu K, Shi C, Toral-Barza L, Lucas J, Shor B, Kim JE et al (2010) Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. Cancer Res 70, 621–31
Guertin DA, Sabatini DM (2009) The pharmacology of mTOR inhibition. Sci Signal. 2, pe24
Shor B, Gibbons JJ, Abraham RT, Yu K (2009) Targeting mTOR globally in cancer: Thinking beyond rapamycin. Cell Cycle 8, 831–37
Toral-Barza L, Zhang WG, Lamison C, Larocque J, Gibbons J, Yu K (2005) Characterization of the cloned full-length and a truncated human target of rapamycin: Activity, specificity, and enzyme inhibition as studied by a high capacity assay. Biochem Biophys Res Commun 332, 304–10
Yu K, Lucas J, Zhu T, Zask A, Gaydos C, Toral-Barza L et al (2005) PWT-458, A Novel Pegylated-17-Hydroxywortmannin, Inhibits Phosphatidylinositol 3-Kinase Signaling and Suppresses Growth of Solid Tumors. Cancer Biol Ther 4, 538–545
Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, Shor B et al (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69, 6232–40
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Yu, K., Toral-Barza, L. (2012). Biochemical and Pharmacological Inhibition of mTOR by Rapamycin and an ATP-Competitive mTOR Inhibitor. In: Weichhart, T. (eds) mTOR. Methods in Molecular Biology, vol 821. Humana Press. https://doi.org/10.1007/978-1-61779-430-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-61779-430-8_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-429-2
Online ISBN: 978-1-61779-430-8
eBook Packages: Springer Protocols